An unbiased metagenomic search for infectious agents using monozygotic twins discordant for chronic fatigue by Sullivan, Patrick et al.
RESEARCH ARTICLE Open Access
An unbiased metagenomic search for infectious
agents using monozygotic twins discordant
for chronic fatigue
Patrick F Sullivan1,2*, Tobias Allander3, Fredrik Lysholm4,5, Shan Goh3, Bengt Persson4,5, Andreas Jacks2,
Birgitta Evengård6, Nancy L Pedersen2, Björn Andersson4*
Abstract
Background: Chronic fatigue syndrome is an idiopathic syndrome widely suspected of having an infectious or
immune etiology. We applied an unbiased metagenomic approach to try to identify known or novel infectious
agents in the serum of 45 cases with chronic fatigue syndrome or idiopathic chronic fatigue. Controls were the
unaffected monozygotic co-twins of cases, and serum samples were obtained at the same place and time.
Results: No novel DNA or RNA viral signatures were confidently identified. Four affected twins and no unaffected
twins evidenced viremia with GB virus C (8.9% vs. 0%, p = 0.019), and one affected twin had previously undetected
hepatitis C viremia. An excess of GB virus C viremia in cases with chronic fatigue requires confirmation.
Conclusions: Current, impairing chronic fatigue was not robustly associated with viremia detectable in serum.
Author Summary
The cause of chronic fatigue syndrome is unknown but
infections with viruses have been suspected. We used a
new approach to screen blood samples for the pre-
sence of known or novel viral infections. Samples were
45 cases with chronic fatigue syndrome or idiopathic
chronic fatigue, and controls were their unaffected
monozygotic co-twins. No novel DNA or RNA viral
signatures were confidently identified. Four affected
twins and no unaffected twins evidenced viremia with
GB virus C (8.9% vs. 0%, p = 0.019), and one affected
twin had previously undetected hepatitis C viremia. An
excess of GB virus C viremia in cases with chronic
fatigue requires confirmation. However, current,
impairing chronic fatigue was not robustly associated
with viral infections in serum detectable by our
methods.
Background
Chronic fatigue syndrome (CFS) is characterized by
prolonged and impairing fatigue of unknown etiology
[1,2]. The standard definition of CFS requires severe
fatigue of over six months duration that remains unex-
plained despite appropriate clinical medical evaluation
along with four of eight signs and symptoms (e.g.,
post-exertional malaise and impaired memory or con-
centration). Immune dysfunction is a major etiological
hypothesis, and could result from a chronic infection
or an inappropriate response to an initial infection
[3-7]. Multiple studies have investigated the possible
role of a range of specific viruses in CFS by searching
for case-control differences in past or current viral
infection (e.g., cytomegalovirus, Epstein-Barr virus,
hepatitis C, human herpes virus-6, and parvovirus B19)
[5]. Inconsistent findings across studies are normative.
The most recent example is xenotropic murine leuke-
mia virus-related virus (XMRV) which was claimed to
be present in 67% of cases with CFS and 3.7% of con-
trols [8] but did not replicate in multiple independent
samples [9]. A recent report found an association
between a different retrovirus (murine leukemia virus)
and CFS (87% of cases, 7% of controls) [10]. The status
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of any connection between XMRV and CFS is remains
highly controversial [11].
It is possible that the etiology of CFS is not unitary.
Non-replication across samples would be expected if
different combinations of etiological processes were
operative in different case sets. Alternatively, inconsis-
tent findings across case-control studies could be due
to bias if controls are inappropriate to cases. For
example, in the initial XMRV study, cases were highly
selected (chronically ill patients treated in medical
practices specializing in CFS) and controls were
described only as “healthy” [8]. Although such indivi-
duals are relatively uncommon, the study of discordant
monozygotic twins offers substantially improved
experimental control (i.e., an individual affected with
CFS and their well monozygotic twin) [12]. We are
aware of one previous study that assessed 22 pairs of
monozygotic twins discordant for CFS for indices of
past and current viral infection (BK virus; cytomegalo-
virus; Epstein-Barr virus; hepatitis C virus; herpes sim-
plex virus 1 and 2; human herpes virus 6, 7, and 8; JC
virus; parvovirus B19; and varicella zoster virus): no
significant or clinically important differences were
found between affected and unaffected twins [13].
An additional limitation has been the reliance on
assays for specific infectious agents. Viruses have tradi-
tionally been identified by culture techniques and more
recently via a variety of molecular approaches. However,
these methods have severe limitations and leave many
viruses undetected. We have developed a complete
“metagenomic” system for systematic identification of
unknown viruses. The discovery pipeline has four com-
ponents: virus enrichment, amplification of genomic
viral DNA or RNA, large scale sequencing, and identifi-
cation of known and novel viral sequences using bioin-
formatics. This powerful strategy has identified two new
viruses, human bocavirus [14] and KI polyomavirus [15]
which cause acute respiratory illness in children.
In this study, 45 pairs of monozygotic twins discor-
dant for chronic fatigue were used in an exhaustive
study to identify risk factors [12]. We report here the
results of screening for viruses in these samples using
metagenomic sequencing. Deep sequencing revealed the
presence of several viruses in cases with chronic fatigue,
particularly GB virus C.
Results
The patient set consisted of 45 pairs of monozygotic
twins discordant for clinically-evaluated chronic fati-
guing illness (Table 1). Most pairs were female (89%),
and the median age at evaluation was 51 years. Of the
affected twins, 32 met criteria for CFS and 13 for ICF
with a median duration of chronic fatigue of 8 years
with no significant difference between affected twins
with CFS and ICF (p = 0.75). Body mass index was simi-
lar between the affected and unaffected twins. Affected
twins had significantly worse physical and mental func-
tioning on the SF-36 [16] and reported significantly
greater current fatigue. The mean functioning of
affected twins was over a standard deviation worse than
Swedish norms whereas the unaffected twins were simi-
lar to Swedish norms (http://www.sf-36.org/nbscalc/
index.shtml, accessed 12 December 2008).
Using metagenomic sequencing to identify
viral signatures
Serum samples from the affected and unaffected twins
were pooled separately and enriched for viral particles.
This resulted in four samples to be sequenced in order
to detect RNA and DNA viruses: a DNA sample and a
cDNA sample for pooled samples from affected and
unaffected twins. Sanger sequencing was performed
from all four samples, resulting in a total of 1,549
sequences from affected twins and 1,513 from unaf-
fected twins. Automated BLAST searches followed by
manual inspection showed that all reads from the unaf-
fected twins were from background contamination
(mostly human or bacterial) or from reagents used for
the library preparation (Figure 1). A small number of
sequences showed no or only insignificant BLAST hits
but manual inspection did not reveal any artifacts and
these could represent low abundance viral sequences. In
Table 1 Description of 45 monozygotic twin pairs discordant for chronic impairing fatigue
Variable Affected twins Unaffected co-twins Statistical comparison
Met criteria for chronic fatigue syndrome 32/45, 71% 0/45, 0% By design
Met criteria for idiopathic chronic fatigue 13/45, 29% 0/45, 0% By design
Female sex 40/45, 89% 40/45, 89% Identical by design
Median age at evaluation, IQR 51, 39-59 years 51, 39-59 years Identical by design
Median body mass index, IQR 25, 22-30 kg/m2 24, 22-31 kg/m2 Paired t44 = 0.1, p = 0.91
Median SF-36 physical function, IQR 41, 27-48 48, 39-52 Paired t44 = 3.1, p = 0.003
Median SF-36 mental function, IQR 39, 29-48 51, 39-56 Paired t44 = 4.7, p = 3 × 10
-5
Median current fatigue by VAS, IQR 69, 49-77 19, 10-51 Paired t43 = -7.2, p = 6 × 10
-9
Abbreviations: IQR = inter-quartile range, VAS = visual analogue scale (0-100).
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contrast, the sequences from the pool of affected twins
showed multiple hits to two known human viruses. In
total, 168/1,549 sequences showed a significant BLAST
identity to GB virus C (GBV-C) and 15/1,549 to hepati-
tis C virus. The numbers of sequences were relatively
high indicating that one or more affected twins had
high copy numbers for these viruses. No other signifi-
cant hits to human viruses were observed.
A next-generation sequencing technology, Roche 454
FLX, was used to search for rare viruses in samples
from affected twins. A total of 53,985 sequence reads
(9.1 Mb) were produced from the DNA sample and
305,191 reads (59.5 Mb) from the RNA (+RT) sample.
The six-fold difference in the numbers of reads was
most likely caused by different efficiencies of the 454
library preparation and the amounts of DNA obtained.
The reads were analyzed using our BLAST search pipe-
line, both unassembled and assembled (together with
the Sanger reads after removal of most human
sequences) using the miraEST assembler. The assembly
results are shown in Tables 2, 3, and 4. The BLAST
results are summarized in Figure 2 and Additional file 1
Figures S1 and S2. For most reads, both hits passed
very high BLAST and coverage thresholds (“classified”)
and those with slightly lower BLAST scores (“remain”)
represent background contamination. Several hundred
reads and some contigs showed very weak or no BLAST
hits and there are some weak hits to known virus
families. However, none were judged to be clear-cut
candidates for novel viruses.
Notably, 29,463 454 reads and 7,105 contigs showed
high BLAST identity with GBV-C. As expected for the
RNA virus GBV-C, 99.5% of the reads came from the
RNA (+RT) fraction (Figure 3). Similarly 1,354 reads
and 162 contigs contained Hepatitis C virus sequences,
almost entirely from the RNA fraction. These results
confirmed the significant presence of these viruses in
samples from the affected twins. Due to the efficient
virus particle enrichment procedure used, it is highly
likely that these sequences come from free virus
particles and that one or more patients have chronic
infection of these viruses.
Confirmation in individual samples
GB virus C
Assessment of the individual samples using nested PCR
showed that four samples from affected twins (8.9%)
and zero from unaffected twins (0%) were positive for
GBV-C. One affected twin had ICF and the rest had
CFS. The first round PCR gave a visible product in all
four positive cases indicating at least moderately high
viral copy number. Detection of GBV-C in affected
co-twins was slightly but significantly higher than
chance expectations (using conditional logistic regres-
sion to account for paired sampling, likelihood
ratio 5.54, df = 1, p = 0.019).
To assess GBV-C sequence diversity, 28,451 sequence
reads from the RNA fraction matching the GBV-C gen-
ome were compared with the 23 complete GBV-C gen-
ome sequences found in Genbank. Using strict BLAST
score criteria, the GBV-C samples in our data set were
found to be quite diverse as regions from 19 of the
complete genomes were represented in the dataset.
A.
B.
Figure 1 Comparison of BLAST results from Sanger reads
(post-assembly) that were classified with high confidence from
twins affected with chronic fatiguing illness (panel A) and their
unaffected co-twins (panel B). The results show a large viral
fraction in affected samples and no viral sequences in unaffected
samples.
Table 2 Results from metagenomic sequencing
Library Type Reads Mean Max MBp
454 DNA 53,984 170 bp 397 bp 9.1 mb
Sanger DNA affected twins 787 716 bp 950 bp 0.56 mb
Sanger DNA unaffected twins 756
454 RNA 305,191 195 bp 331 bp 59.5 mb
Sanger RNA affected twins 762 720 bp 1412 bp 0.59 mb
Sanger RNA unaffected twins 757
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However, 51% of the sequences (14,667 of 28,451) were
divided between five different isolates in roughly equal
numbers. GBV-C is known to vary extensively between
isolates and the large diversity revealed here indicates
that these four affected twins were infected by different
isolates and that different variants are present in each
individual.
Hepatitis C virus
A standard diagnostic serology test confirmed previously
unrecognized hepatitis C infection in one affected twin.
This discovery provides a plausible medical explanation
for chronic fatigue in this individual.
Discussion
We used an “unbiased” genomic technology to search
for the presence of known and novel viruses that corre-
late with the clinical presence or absence of chronic fati-
guing illness. Such searches have proven powerful for
respiratory infections [14,15], and complement studies
targeting specific infectious agents [13]. The general
hypothesis we tested was that chronic fatigue was asso-
ciated with on-going viremia. As we have argued else-
where [12], the study of discordant monozygotic twins
was optimal in controlling for potential biases particu-
larly as samples were obtained from both twins at the
same place and time.
The deep Roche 454 sequencing, combined with the
efficient enrichment of virus particles, makes it likely
that most viruses present in the serum of these indivi-
duals were detected. However, we did not detect any
clear-cut signatures of novel viruses. For known viruses,
the predominant finding was a slight but significant
excess of detection of nucleic acid from GBV-C in 8.9%
of affected twins and 0% of their unaffected co-twins
(p = 0.019). Previously undetected hepatitis C virus
infection was discovered in one affected twin. This
individual was kept in these analyses as this is conserva-
tive and conforms to our prior intentions.
GBV-C (also known as hepatitis G virus) is an RNA
virus and member of the Flaviviridae family with great-
est homology to hepatitis C virus. It is transmitted via
multiple modalities (e.g., vertically, sexually, and parent-
erally) [17]. GBV-C viremia is present in ~2% of healthy
blood donors and 17% show evidence of past infection
[18]. GBV-C infection is not known to cause any human
disease [19] and co-infection might improve the course
of HIV-1 disease [20]. A prior small study of 12 CFS
cases and 21 controls concluded that chronic GBV-C
infection was not associated with CFS [21]. The lack of
GBV-C positive individuals among the unaffected twins
is could at first glance be seen as surprising. However,
we would statistically expect that one or two individuals
would be positive, based on chance, and the result we
obtained is therefore not unlikely.
There are several reasons why a chronic infection
important to the etiology of chronic fatiguing illness
could have escaped detection. For example, viral titers
might be beneath the detection limit of our approach,
the infection might be intermittently active and not dur-
ing our sampling, and a salient infection might occur in
body compartments or tissues where viral particles do
not appear in blood. It is also possible that a salient
infection occurred earlier in life, was cleared, but the
infection sequelae are responsible for clinical state. Such
infections, in the case of known viruses, can in many
Table 3 Removal of reads matching the human genome
sequences
Library Type Reads Human reads screened After screening
454 DNA 53,984 20,376 33,608
Sanger DNA 787 246 541
Total DNA 54,771 20,622 34,149
454 RNA 305,191 263,436 41,755
Sanger RNA 762 450 312
Total RNA 305,953 263,886 42,067
Table 4 miraEST assembly of non-human sequence reads
Library Contigs Max/mean length Reads/contig Singletons Max/mean length
DNA 1,875 1,679/214 6.15 17,640 396/184
RNA 4,541 2,779/350 7.22 6,374 330/191
Figure 2 BLAST results from Roche 454 reads that were
classified with high confidence from affected samples after
pre-assembly screening removing high confidence human and
repetitive sequences. A large viral fraction can be seen.
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cases be detected via serology. Finally, it is possible that
chronic fatiguing illness represents a similar clinical
endpoint for multiple different disease etiologies (which
may or may not be infectious in nature) and that etiolo-
gical heterogeneity effectively lessens the probability of
detection.
Conclusions
Our results show a weakly significant difference between
affected and unaffected twins in the cross-sectional pre-
valence of GBV-C viremia. Whether this is etiologically
important or due to chance or bias is not clear. How-
ever, the possible connection between GBV-C and CFS
deserves further study in larger samples.
Methods
Subjects
The protocol was approved in advance by the ethical
review board at UNC-CH and the Karolinska Institutet
and all subjects provided written informed consent. The
parent study is described elsewhere [22-24], and we
have previously shown that there were no differences in
gene expression in peripheral blood in monozygotic
twins discordant for chronic fatigue [12]. We screened
~61,000 individual twins from the Swedish Twin Regis-
try for the symptoms of fatiguing illness. All twins were
born in Sweden of Scandinavian ancestry. Of 5,597
monozygotic twin pairs where both were alive and had
provided usable responses to CFS screening questions,
we identified 140 pairs of twins who met preliminary
inclusion criteria: born 1935-1985, classified as a mono-
zygotic twin based on questionnaire responses [25], and
discordant for chronic fatiguing illness (i.e., one twin
reported substantial fatigue and the other twin was evi-
dently well). A telephone interview using a standardized
script was used to assess eligibility for participation.
Twins who remained eligible both attended a half-day
clinical assessment by a specially trained physician at
the Karolinska Institutet in Stockholm. At this visit, a
CFS-focused medical assessment was conducted that
included standardized medical history, physical examina-
tion, and screening biochemical, hormonal, and hemato-
logical studies in accordance with international
recommendations [1].
Of 140 monozygotic and preliminarily discordant twin
pairs, one or both twins declined participation in
23 pairs, 25 pairs were concordant for CFS-like illness,
and inclusion criteria were not met in 35 pairs
(e.g., chronic fatigue had resolved or an illness that
could explain fatiguing symptoms such as neoplasia had
emerged). After excluding these 83 pairs, 57 pairs of
twins attended the clinical evaluation sessions, and 10
pairs were found not to meet inclusion criteria (9 pairs
were concordant for the presence or absence of chronic
fatigue or a medical explanation was detected and 1 pair
was dizygotic). Serum samples were unavailable for both
members of 2 pairs. Zygosity was confirmed by genotyp-
ing 46 single nucleotide polymorphisms using two
Sequenom iPlex panels.
The analysis sample consisted of 45 pairs of rigorously
discordant and genetically proven monozygotic twins.
Discordance was defined as one twin meeting criteria
for either idiopathic chronic fatigue (ICF, 13 pairs) or
CFS (32 pairs) [1,2] and the co-twin was required never
to have experienced impairing unusual fatigue or tired-
ness lasting more than one month. Thus, all affected
twins were required to have current, long-standing (≥6
months), medically unexplained fatigue associated with
substantial impairment in social and occupational func-
tioning and the unaffected co-twins were effectively well.
Biological sampling
Biological sampling was standardized by having samples
drawn from both members of a twin pair at the same
place and time (~0900) after an overnight fast. We
required that all subjects be in their usual state of health
on the day of sampling (i.e., no acute illness or recent
exacerbation of a chronic illness). It was neither
A.
B.
Figure 3 Further classification of BLAST hits into virus families.
The sequences are 454 sequences from CFS patients classified with
high confidence (panel A) and by closest homologue (panel B).
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practical nor ethical to study subjects medication-free,
but we delayed assessment if there had been a recent
significant dosage change. Peripheral venous blood was
drawn using sterile technique.
Viral library preparation and sequencing
Serum samples from 45 pairs of affected and unaf-
fected monozygotic twins were available for this study.
Sample preparation for library construction was as
described previously [14] and, briefly, consists of viral
particle recovery and nucleic acid extraction, followed
by amplification and cloning of viral nucleic acid.
Serum samples (200 μl) from the affected twins were
pooled separately from their unaffected co-twins.
Serum pools were then filtered either through 0.22 μm
or 0.45 μm membrane filters (Millipore) and virus par-
ticles were concentrated by ultracentrifugation (41,000
rpm for 1.5 h at 4°C in a Beckman SW41 rotor). Exo-
genous nucleic acids were removed by DNaseI and
RNaseA treatment followed by extraction of viral DNA
(Qiagen) or RNA (Trizol, Invitrogen). First strand
synthesis was carried out with a random primer con-
taining an EcoRV site plus exonuclease negative Kle-
now polymerase (Promega) for DNA and Superscript
II reverse transcriptase (Invitrogen) for RNA. Second
strand synthesis for the above reactions was carried
out with exonuclease negative Klenow polymerase
(Promega). These were then amplified with AmpliTaq
Gold polymerase (Applied Biosystems) and a primer
complementary to part of the random primer used in
first strand synthesis. PCR products were purified,
digested with EcoRV, subjected to gel electrophoresis,
and bands 500 bp - 5 kb were extracted from the gels.
Blunt-ended PCR products were then cloned into
pCR-blunt (Invitrogen) and transformed into TOP10
chemically competent cells for sequencing of clones.
The library was then verified using conventional San-
ger sequencing with DYEnamic Dye Terminator kits
and a Megabace 1000 sequencer (GE Healthcare). Gel-
purified blunt-ended PCR products (1.25-1.35 μg) were
subjected to ultra-deep sequencing using the 454 FLX
chemistry and sequencer (Roche) according to the
manufacturer’s instructions at the time.
Computational analysis
Even though enriched for viruses, most of the sequenced
samples contained a large fraction of human reads. For
the purpose of analyzing the viral content of the data,
human reads can be removed from the samples before
assembly without affecting the results. The benefits of
removing human sequences pre-assembly include a
heavily reduced assembly time and a reduced risk of
mis-assembly. Most human reads are highly homologous
to human database sequences and can be identified with
MegaBLAST [26]. Multiple NCBI databases (i.e., EST-
Human, Human Genomic, and Human Genomic Tran-
scripts) [27] were used to identify human reads. Highly
repetitive human reads identified by MegaBLAST were
also discarded. The remaining overlapping reads were
then assembled into contigs using miraEST [28] which
can perform a hybrid assembly using both Roche/454
and traditional Sanger sequences.
Before attempting to classify the contigs and single-
tons, highly repetitive sequences were eliminated using
the DUST algorithm [29]. Remaining sequences were
classified through a protocol of database alignment
searches using NCBI BLAST [30]. Alignment search
tools trade speed for sensitivity: for metagenomic data-
sets, efficient identification of more distantly homolo-
gous matches is accomplished using progressively more
sensitive searches (rather than a single sensitive search).
Progressive searches were performed using MegaBLAST
against NCBI NT, then using BLASTn against NCBI
NT, and finally using BLASTx against NCBI NR. For
example, for a set of Roche/454 RNA reads, 70% of the
remaining sequences were classified in the first step
leaving far fewer data for the more time-consuming sec-
ond and third steps. Sequences were then classified
using the closest homologue defined by the alignment
searches. Two main categories were built: classified
sequences that are highly similar to a database sequence
(> 90% identity with >70% query coverage) and “remain-
der” sequences that may contain new findings. Each
category was split into taxonomy divisions and the virus
division was further split into suitable virus subgroups
to aid analysis.
Total nucleic acid extraction and PCR of individual serum
samples
Serum samples (400 μl each) were used for total nucleic
extraction using the Virus Mini M48 kit (Qiagen)
according to the manufacturer’s instructions. The auto-
mated extraction process was carried out in a Qiagen
Biorobot M48.
Presence of GBV-C virus in the samples was confirmed
by nested PCR with primers specific for the 5’ UTR of
virus RNA [31]. First-round, one-step RT-PCR consisted
of 1× AmpliTaq buffer (Applied Biosystems), 2 mM
MgCl2, 200 μM dNTP mix, 0.4 μM of each primer GBV-
F1 (5’ CGGCCAAAAGGTGGTGGATG 3’) and GBV-R1
(5’ CACTGGTCCTTGTCAACTCG 3’), 5 μl of sample, 4
units AMV RT (Promega), 16 units of RNasin (Promega)
and 1 unit of AmpliTaq DNA polymerase in a 50μl reac-
tion. Cycling conditions were: 42°C for 60 min, and 35
cycles of 95°C for 1.5 min, 55°C for 2 min, 72°C for 3 min.
The expected product size was 299 bp. Five μl of the first
round reaction was used for a second round PCR reaction,
which consisted of 1× AmpliTaq buffer, 2 mM MgCl2,
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200 μM dNTP mix, 0.4 μM of each primer GBV-F2
(5’ GGTGATGACAGGGTTGGTAG 3’) and GBV-R2
(5’ GCCTATTGGTCAAGAGAGACAT 3’), 1.25 U
AmpliTaq DNA polymerase in a 50μl reaction. Reaction
conditions were 94°C for 10 min, 35 cycles of 94°C for
30 s, 60°C for 30 s, 72°C for 1 min, and 72°C for 10 min-
utes. The expected PCR product size was 251 bp.
The diversity of GBV-C reads were compared against
a database of complete GBV-C genome sequences from
Genbank (23 sequences) using BLAST. A sequence was
classified as similar to a certain isolate if the BLAST hit
e-value was < 10-20 and if the top hit was at least 100
times more significant than the second hit.
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